Swiss drugmaker Novartis AG is selling its 70.68% stake in its Indian unit for Rs 1,446 crore to a consortium led by ChrysCapital. This divestment aligns with Novartis' strategy to become a pure-play innovative medicines company, while it maintains a significant presence in India through its wholly owned subsidiary.
